The global oncology biosimilar market size was estimated at USD 8.00 billion in 2025, and is anticipated to grow from USD 9.48 billion in 2026 till USD 36.90 billion in 2034, growing at a CAGR of 18.5% from 2026-2034.
Oncology biosimilars are biologic medicines developed to be highly similar to approved reference biologics used in the treatment of cancer, with no clinically meaningful differences in safety, efficacy, or quality. They are manufactured using living cells and undergo rigorous regulatory evaluation to ensure comparable therapeutic performance. These products help expand patient access to advanced cancer therapies while supporting cost efficiency and broader adoption of biologic treatments.
Download a Free Sample To learn more about this report,
Increasing Adoption of Cost-Effective Biosimilar Cancer Therapies
The Oncology Biosimilar market trends are being driven by the increasing demand for affordable cancer treatments, wider regulatory support, and the growing number of biologic drug patent expirations. Healthcare providers are increasingly adopting oncology biosimilars because they provide clinical outcomes comparable to reference biologics while lowering treatment costs and improving patient access. Governments and healthcare systems are also encouraging biosimilar prescribing to reduce healthcare spending and expand access to advanced cancer therapies. In addition, pharmaceutical companies are investing in biosimilars for monoclonal antibodies used in breast cancer, colorectal cancer, and blood cancers, while improving manufacturing technologies and supply chains. These developments are helping increase the availability of high-quality oncology biologics and supporting broader use of targeted cancer treatments across hospitals and oncology centers worldwide.
These developments indicate that affordable biologic therapies, expanding biosimilar approvals, increasing physician confidence, and broader regulatory support will remain the key Oncology Biosimilar market trends, improving patient access, reducing treatment costs, and accelerating the adoption of advanced cancer therapies worldwide.
Increasing Cancer Burden and Demand for Cost-Effective Biologics
The oncology biosimilar market is expanding due to the rising global burden of cancer and the growing demand for affordable biologic therapies. According to the World Health Organization, nearly 20 million new cancer cases were diagnosed globally in 2022, increasing the need for accessible oncology treatments. As patents for several blockbuster biologics continue to expire, healthcare providers are increasingly adopting biosimilars to reduce treatment costs while maintaining comparable safety and efficacy. Favorable government policies, reimbursement support, and broader physician acceptance are also accelerating biosimilar adoption across oncology care.
Stringent Regulatory Requirements and Limited Physician Acceptance
The oncology biosimilar market faces challenges due to stringent regulatory approval requirements and limited physician confidence in certain regions. Biosimilar manufacturers must conduct extensive analytical, clinical, and comparative studies to demonstrate similarity with reference biologics, increasing development costs and approval timelines. Patent litigation and intellectual property disputes also delay product launches in several countries. Additionally, concerns regarding product interchangeability, immunogenicity, and brand preference continue to influence prescribing decisions in some healthcare systems.
Expansion of Biosimilar Portfolios and Emerging Healthcare Markets
The oncology biosimilar market is expected to benefit from the continued expansion of biosimilar product portfolios and increasing healthcare investments in emerging economies. Patent expirations of additional oncology biologics are creating opportunities for manufacturers to introduce new biosimilar therapies. Governments and healthcare providers are promoting biosimilar adoption to improve treatment affordability and expand patient access. Advances in biomanufacturing technologies and strategic partnerships between pharmaceutical companies are also accelerating product development and commercialization across global markets.
Manufacturing Complexity and Intense Market Competition
The oncology biosimilar market continues to face challenges related to manufacturing complexity, pricing pressure, and intense competition. Producing biosimilars requires sophisticated manufacturing facilities, advanced quality control systems, and strict regulatory compliance to ensure product consistency. Competition among multiple biosimilar manufacturers has intensified price erosion in several mature markets, affecting profit margins. In addition, maintaining reliable supply chains and educating physicians and patients about biosimilar safety and efficacy remain important challenges for market participants.
Request Customizationto receive a tailored report.
Monoclonal Antibodies (mAbs) Dominated the Market with 52% Share in 2025
The Monoclonal Antibodies (mAbs) segment accounted for the largest share of the global oncology biosimilar market at 52% in 2025, driven by the high adoption of biosimilar versions of blockbuster cancer therapies, increasing regulatory approvals, and growing demand for cost-effective biologic treatments.
Lung Cancer is Projected to Register the Fastest Growth at a CAGR of 17.1%
The Lung Cancer segment is expected to expand at the highest CAGR of 17.1% during 2026–2034, supported by the rising incidence of lung cancer, increasing use of targeted biologic therapies, and wider availability of biosimilars that improve treatment affordability.
Intravenous (IV) Dominated the Market with 68% Share in 2025
The Intravenous (IV) segment held the largest share of the global oncology biosimilar market at 68% in 2025, owing to the widespread use of intravenous biologics in hospital-based cancer treatment, established clinical protocols, and the need for supervised administration.
Online Pharmacies are Projected to Register the Fastest Growth at a CAGR of 19.3%
The Online Pharmacies segment is anticipated to witness the fastest growth, registering a CAGR of 19.3% during 2026–2034, driven by expanding digital healthcare platforms, increasing patient preference for home delivery services, improved access to specialty medicines, and the growing adoption of e-pharmacy services.
Speak to an Analystto discuss market opportunities.
North America dominated the global oncology biosimilar market with a 38.0% market share, valued at USD 3.04 billion in 2025. The region benefits from advanced oncology care infrastructure, favorable regulatory pathways for biosimilar approvals, increasing adoption of cost-effective biologics, and strong reimbursement support. Rising cancer prevalence, growing healthcare expenditure, and expanding physician confidence in biosimilars continue to accelerate market growth across the region.
The United States accounted for an estimated USD 2.58 billion of the market in 2025, making it the largest contributor in North America. Growth is driven by increasing biosimilar approvals, expanding use of biosimilar monoclonal antibodies in cancer treatment, strong payer support, and the presence of major pharmaceutical companies investing in oncology biosimilars.
Canada generated an estimated USD 0.46 billion in 2025. Rising healthcare investments, expanding biosimilar adoption programs, increasing demand for affordable cancer therapies, and supportive government reimbursement initiatives continue to drive market growth across the country.
Europe accounted for 31.0% of the global oncology biosimilar market, reaching USD 2.48 billion in 2025. The market is supported by well-established biosimilar regulatory frameworks, high physician acceptance, increasing healthcare cost-containment strategies, and widespread adoption of biosimilar oncology products. Continued investment in biologic manufacturing and favorable reimbursement policies further support regional growth.
The United Kingdom represented an estimated USD 0.50 billion in 2025. The country's market is driven by NHS initiatives promoting biosimilar adoption, increasing oncology treatment demand, expanding access to biologic therapies, and efforts to reduce healthcare costs through biosimilar utilization.
Germany led the European market with an estimated value of USD 0.69 billion in 2025. The country's advanced healthcare infrastructure, strong biosimilar uptake, growing cancer burden, and favorable reimbursement environment continue to support sustained market expansion.
Asia Pacific accounted for 22.0% of the global oncology biosimilar market, valued at USD 1.76 billion in 2025, and is projected to register the fastest CAGR of 18.7% during the forecast period. Rising cancer incidence, expanding healthcare infrastructure, increasing government support for biosimilars, and growing domestic biologics manufacturing are accelerating market growth across the region.
Japan generated an estimated USD 0.32 billion in 2025. The country's aging population, increasing cancer prevalence, supportive biosimilar policies, and expanding adoption of advanced biologic therapies continue to fuel market growth.
China accounted for an estimated USD 0.74 billion in 2025, making it the largest market in the Asia Pacific. Government healthcare reforms, increasing domestic biosimilar production, expanding oncology treatment access, and rising investments in biopharmaceutical research continue to drive strong market growth.
The Middle East & Africa represented 4.0% of the global oncology biosimilar market, totaling USD 0.32 billion in 2025. Increasing healthcare investments, improving access to cancer treatment, expanding adoption of biosimilars, and growing awareness of affordable biologic therapies are supporting regional market growth.
The United Arab Emirates (UAE) accounted for an estimated USD 0.08 billion in 2025. The country's market is driven by government investments in oncology care, expanding specialty healthcare facilities, increasing access to biosimilar therapies, and growing demand for cost-effective cancer treatments.
Africa is witnessing steady growth in the oncology biosimilar market, supported by improving oncology care infrastructure, increasing cancer awareness, expanding healthcare investments, and greater availability of affordable biologic medicines. Countries such as South Africa, Egypt, and Kenya are strengthening cancer treatment capabilities, creating long-term growth opportunities for oncology biosimilar manufacturers.
Unlock Regional Insightsto access country-level data, & regional trends.
Customize This Report to Match Your Strategic Objectives
Author's Details
Healthcare Lead
Debashree Bora is a Healthcare Lead with over 7 years of industry experience, specializing in Healthcare IT. She provides comprehensive market insights on digital health, electronic medical records, telehealth, and healthcare analytics. Debashree’s research supports organizations in adopting technology-driven healthcare solutions, improving patient care, and achieving operational efficiency in a rapidly transforming healthcare ecosystem.
We are featured on:
sales@straitsresearch.com